1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1:

Presence and distribution of the citrulline peak in patients with MS according to the VOI site revealed by 1H-MR Spectroscopy

Patient No.Citrulline Peak on 1H-MR Spectroscopy
NAWMCDLEDL
1+na
2na
3nana
4+
5nana
6++na
7++na
8na
9+na
10+
11na
12+
13+na
14
15
16na
17nana
18++
19na
20na
21++
22+na
23na
24+na
25na
26na
27na
  • Note:—na indicates that MR spectroscopy could not be performed due to absence of such a VOI site; +, present; –, absent; MS, multiple sclerosis; VOI, voxel of interest; NAWM, normal-appearing white matter; CDL, chronic demyelinating lesions; EDL, enhanced demyelinating lesions.